Japan Approves St. Jude Medical Defibrillation Leads
This article was originally published in PharmAsia News
U.S. medical device maker St. Jude Medical says Japanese authorities have approved its Durata high-voltage defibrillation lead. The device is the smallest high-voltage lead in terms of diameter on the market, making it particularly helpful in treating patients with constricted blood flow or similar problems. St. Jude Chairman Paul Bond said the approval by Japan's Ministry of Health, Labor and Welfare would enhance the company's global market for its leads. (Click here for more
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.